AXL and non-small cell lung carcinoma: As BGB324 has been launched into a clinical trial as a second-line treatment for patients who develop resistance after EGFR TKI treatment (NCT02424617), our results suggest that AXL inhibition may be explored as a second-line or potential adjuvant treatment for NSCLC harboring the EGFR C797S mutation.